恒瑞医药：三个药物获临床试验批准

Core Insights - The company announced that its subsidiaries Suzhou Shengdiya, Shanghai Hengrui, and Shanghai Shengdi Pharmaceutical received clinical trial approval from the National Medical Products Administration for three injectable drugs [1] Group 1: Drug Development - SHR-A2102 is an antibody-drug conjugate developed by the company, with a cumulative R&D investment of approximately 225 million yuan [1] - SHR-1802 is a humanized monoclonal antibody, with a cumulative R&D investment of about 62.09 million yuan [1] - Adebali monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody, with a cumulative R&D investment of around 939 million yuan [1] Group 2: Clinical Research - These drugs will be used in Phase I B/II clinical studies for advanced solid tumors [1]